LT2796171T - Amisulprido panaudojimas opiatų sukelto pykinimo ir vėmimo gydymui - Google Patents

Amisulprido panaudojimas opiatų sukelto pykinimo ir vėmimo gydymui

Info

Publication number
LT2796171T
LT2796171T LTEP14173186.9T LT14173186T LT2796171T LT 2796171 T LT2796171 T LT 2796171T LT 14173186 T LT14173186 T LT 14173186T LT 2796171 T LT2796171 T LT 2796171T
Authority
LT
Lithuania
Prior art keywords
opiated
amisulpride
vomiting
treating
induced nausea
Prior art date
Application number
LTEP14173186.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2796171(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Limited filed Critical Acacia Pharma Limited
Publication of LT2796171T publication Critical patent/LT2796171T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP14173186.9T 2010-03-11 2011-03-10 Amisulprido panaudojimas opiatų sukelto pykinimo ir vėmimo gydymui LT2796171T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use

Publications (1)

Publication Number Publication Date
LT2796171T true LT2796171T (lt) 2018-05-10

Family

ID=42136792

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14173186.9T LT2796171T (lt) 2010-03-11 2011-03-10 Amisulprido panaudojimas opiatų sukelto pykinimo ir vėmimo gydymui

Country Status (26)

Country Link
US (12) US8686019B2 (https=)
EP (3) EP2796171B1 (https=)
JP (2) JP5886213B2 (https=)
KR (1) KR101738201B1 (https=)
CN (1) CN102892407B (https=)
AU (1) AU2011225898B2 (https=)
BR (1) BR112012022746B1 (https=)
CA (1) CA2792392C (https=)
CY (3) CY1115485T1 (https=)
DK (3) DK2567690T3 (https=)
EA (1) EA030335B1 (https=)
ES (3) ES2665418T3 (https=)
GB (1) GB201004020D0 (https=)
HR (3) HRP20140744T1 (https=)
HU (1) HUE037088T2 (https=)
IL (1) IL221746A (https=)
LT (1) LT2796171T (https=)
MX (3) MX388787B (https=)
NO (1) NO2796171T3 (https=)
NZ (1) NZ602279A (https=)
PL (3) PL2544657T3 (https=)
PT (3) PT2544657E (https=)
RS (3) RS53467B (https=)
SI (3) SI2796171T1 (https=)
SM (3) SMT201800188T1 (https=)
WO (1) WO2011110854A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP2018530744A (ja) 2015-09-02 2018-10-18 カリフォルニア インスティチュート オブ テクノロジー 低濃度の硫化水素ガスの分光学的検出のための方法および装置
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
KR20220041143A (ko) * 2019-07-31 2022-03-31 아스텔라스세이야쿠 가부시키가이샤 귀내 투여용의 의약 조성물
EP4175631A1 (en) 2020-07-06 2023-05-10 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
JP2026501286A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4735456A1 (en) 2023-06-30 2026-05-06 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CN101410094B (zh) 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
US10085970B2 (en) 2018-10-02
PT2567690E (pt) 2014-09-03
EP2544657A2 (en) 2013-01-16
NO2796171T3 (https=) 2018-06-30
PL2567690T3 (pl) 2014-11-28
US20210228543A1 (en) 2021-07-29
JP2013522181A (ja) 2013-06-13
IL221746A (en) 2017-03-30
PT2796171T (pt) 2018-04-24
NZ602279A (en) 2014-08-29
ES2665418T3 (es) 2018-04-25
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
US9545426B2 (en) 2017-01-17
JP6279526B2 (ja) 2018-02-14
US10525033B2 (en) 2020-01-07
SI2544657T1 (sl) 2014-12-31
CA2792392A1 (en) 2011-09-15
JP2016028090A (ja) 2016-02-25
EP2567690B1 (en) 2014-07-16
KR20130045241A (ko) 2013-05-03
CY1115485T1 (el) 2017-01-04
BR112012022746B1 (pt) 2021-09-28
HRP20140745T1 (hr) 2014-09-26
US9119836B2 (en) 2015-09-01
CN102892407A (zh) 2013-01-23
RS57032B1 (sr) 2018-05-31
MX2012010411A (es) 2012-11-30
DK2544657T3 (da) 2014-08-11
US9084765B2 (en) 2015-07-21
US9889118B2 (en) 2018-02-13
HRP20140744T1 (hr) 2014-09-26
US20150335616A1 (en) 2015-11-26
SI2796171T1 (en) 2018-05-31
CY1120170T1 (el) 2018-12-12
EP2544657B1 (en) 2014-07-16
MX388787B (es) 2025-03-20
ES2496099T3 (es) 2014-09-18
SI2567690T1 (sl) 2014-12-31
WO2011110854A2 (en) 2011-09-15
EA030335B1 (ru) 2018-07-31
PL2544657T3 (pl) 2014-10-31
GB201004020D0 (en) 2010-04-21
CY1115487T1 (el) 2017-01-04
BR112012022746A2 (pt) 2016-07-05
EP2796171B1 (en) 2018-01-31
PT2544657E (pt) 2014-09-03
US20250186394A1 (en) 2025-06-12
US20140147517A1 (en) 2014-05-29
DK2796171T3 (en) 2018-05-07
RS53466B (sr) 2014-12-31
JP5886213B2 (ja) 2016-03-16
EP2796171A1 (en) 2014-10-29
SMT201800188T1 (it) 2018-07-17
CN102892407B (zh) 2016-03-23
HRP20180436T1 (hr) 2018-05-04
US20180042896A1 (en) 2018-02-15
EP2567690A1 (en) 2013-03-13
HUE037088T2 (hu) 2018-08-28
AU2011225898B2 (en) 2014-07-03
SMT201400126B (it) 2015-05-05
DK2567690T3 (da) 2014-08-11
KR101738201B1 (ko) 2017-05-19
CA2792392C (en) 2018-06-19
RS53467B (sr) 2014-12-31
US20130022689A1 (en) 2013-01-24
US8686019B2 (en) 2014-04-01
US20200093792A1 (en) 2020-03-26
HK1179152A1 (zh) 2013-09-27
EA201290833A1 (ru) 2013-09-30
US20170087128A1 (en) 2017-03-30
MX370629B (es) 2019-12-18
US20220296570A1 (en) 2022-09-22
US20180353473A1 (en) 2018-12-13
ES2496092T3 (es) 2014-09-18
MX2019015396A (es) 2020-02-07
SMT201400127B (it) 2015-05-05
US12194022B2 (en) 2025-01-14
AU2011225898A1 (en) 2012-10-04
US20230144973A1 (en) 2023-05-11
US20130022688A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
PT2796171T (pt) Uso de amissulprida como anti-emético
EP2603250A4 (en) Wound treatment and containment arrangement
ZA201303605B (en) Compounds and methods for treating pain
EP2523630A4 (en) SYSTEMS AND METHODS FOR BARIATRIC THERAPY
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
IL226331A0 (en) Bromodomain inhibitors and their use
ZA201305495B (en) Compounds and their use as bace inhibitors
SG2014006068A (en) Isotopically-enriched boron-containing compounds, and methods of making and using same
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
PL2616065T3 (pl) GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
ZA201303773B (en) Compounds and their use
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
IL222479A0 (en) Devices and methods for tissue engineering
EP2566483A4 (en) METHOD AND MEANS FOR IMPROVED WOUND HEALING
GB201011411D0 (en) Therapeutic compounds and their use
EP2624854A4 (en) MOESIN MODULATORS AND ITS USES
GB201016486D0 (en) Compounds for the use in treatment of plants
GB201002337D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201017822D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use